EBO2 (EBOO) for Mold Toxicity and CIRS: Claims vs Evidence

EBO2 (also called EBOO) is marketed to people who believe they are experiencing mold toxicity or chronic inflammatory response syndrome (CIRS) after exposure to a water-damaged building. Clinic pages typically describe the treatment as clearing mycotoxins, the toxic compounds some molds produce, from the bloodstream and reducing the inflammation attributed to them, marketing language similar to what appears in guides to EBO2 for Lyme disease and other hard-to-pin-down chronic symptoms. This guide separates what is medically established about mold exposure from what CIRS actually is as a diagnosis, and lays out what the published literature says, and does not say, about ozone therapy and mycotoxins. For background on the procedure itself, see what EBO2 is.

What mold toxicity and CIRS mean, and how contested they are

CIRS is described by its proponents as an acquired condition involving innate immune dysregulation following exposure to a water-damaged building, producing a wide, multi-system set of symptoms such as fatigue, cognitive complaints, and muscle aches [2]. A 2024 review sympathetic to the diagnosis describes it as under-recognized and underdiagnosed, and states it could affect up to a quarter of the population, a figure that comes from advocates for the diagnosis rather than an independently replicated population study and should be read with that origin in mind [2]. It is not a diagnosis recognized in mainstream allergy, immunology, or occupational medicine practice in the way asthma or an IgE-mediated mold allergy is, and it does not appear in the standard diagnostic manuals those specialties use to code and bill for a condition. A 2024 literature review searching specifically for treatment evidence in CIRS found only 13 articles addressing treatment at all and concluded the only approach with documented clinical efficacy was the Shoemaker Protocol, a specific multi-step regimen of binders, antibiotics, and hormonal treatments developed by the physician who named the condition [2]. That review does not mention ozone therapy, EBO2, or EBOO anywhere as a studied or recommended treatment for CIRS. Mold toxicity as a lay term is used even more loosely than CIRS, and clinic marketing sometimes uses the two interchangeably, applying either label to symptoms as varied as fatigue, joint pain, headaches, and brain fog regardless of how directly they can be tied to a specific exposure.

Established mold health effects

Mold does cause real, well-documented health problems, just not the systemic toxicity some marketing implies. CDC states that mold exposure can cause a stuffy nose, sore throat, coughing or wheezing, burning eyes, or skin rash in sensitive people, and cites a 2004 Institute of Medicine finding of sufficient evidence linking indoor mold exposure to upper respiratory symptoms, cough, and wheeze even in people without allergies [1]. People with asthma or mold allergies can have more severe reactions, and immune-compromised people or those with chronic lung disease are at risk of actual mold infections in the lungs, a distinct and more serious problem than the inflammatory symptoms CIRS proponents describe [1]. Workers who encounter large quantities of mold in occupational settings face higher exposure than typical home occupants, and CDC notes research pointing to a possible link between early mold exposure and the later development of asthma in genetically susceptible children, an association that is about long-term respiratory disease risk, not a general blood-borne toxicity [1]. CDC does not recommend mold testing as a way to determine whether someone will get sick, because health effects vary by person and cannot be predicted by which mold species is present or how much is measured [1]. That position from CDC is worth sitting with, since much of the CIRS and mold-toxicity testing industry is built around exactly the kind of specialty environmental and biomarker panels CDC says will not reliably predict who becomes ill. The established response to a moldy building is removal of the mold and the moisture causing it, not testing the occupant’s blood, and certainly not a blood treatment aimed at symptoms rather than the building itself.

What clinics claim EBO2 does for mold

Clinic pages marketing EBO2 for mold-related illness typically make several specific claims: that the treatment removes mycotoxins and environmental toxins from the bloodstream, reduces systemic inflammation tied to joint pain and headaches, strengthens immune resistance to further toxin exposure, and improves energy and cognitive symptoms through better tissue oxygenation [5][6]. One clinic describes EBO2 as providing deep detoxification at a cellular level, positions it as more direct than conventional approaches such as sauna use or binders, and states plainly that those conventional methods “only provide partial relief” by comparison [6]. Another describes the treatment as “deeply cleansing the blood of toxins and inflammatory byproducts” and “enhancing cognitive function, reducing brain fog and neurological symptoms” [5]. These are claims about what filtration and oxygen/ozone exposure could theoretically do to circulating molecules, not claims backed by a clinical trial in people with mold-related symptoms, and ozone therapy is not FDA-approved to treat any condition, including mold toxicity or CIRS [7].

What the evidence shows

No controlled trial of EBO2, or of any other ozone therapy, has been conducted for mold-related illness or CIRS specifically. The one closely related data point is a single-patient case report: an 88-year-old woman with chronic anemia and a reported history of environmental toxin exposure who underwent two series of EBOO treatment showed an average 64.8 percent decline in a urinary mycotoxin marker ratio, a 25.7 percent average decline in heavy-metal markers, and a 55.1 percent average decline in other environmental toxin markers, though nickel specifically did not decline and hemoglobin was largely unchanged despite the anemia the treatment was also intended to help [4]. That case report has no control group, cannot rule out normal fluctuation or ongoing changes in the patient’s environmental exposure between measurements, and by design cannot show that EBOO caused the observed changes or that they translated into any symptom improvement. A single case cannot generalize into a treatment recommendation.

Separately, ozone genuinely does have a documented role in reducing mycotoxins, but not inside a person. A substantial body of food-science literature, including a 2025 review of ozone technology for grain preservation, documents ozone’s use as an industrial decontamination method for aflatoxins and other mycotoxins in stored grain and nuts, alongside its established role as a biocide against mold and insects in that setting [3]. That literature concerns treating stored crops with ozone gas under controlled industrial conditions, at concentrations and exposure times chosen to degrade mycotoxin molecules sitting in dry grain, an entirely different exposure and mechanism from passing a patient’s blood through an oxygen/ozone exchange device. The existence of one body of evidence does not lend support to the other; a clinic citing research on ozone breaking down mycotoxins is very likely describing this food-safety literature, not anything tested in blood or in patients. No study in that food-science literature involves a human subject at all, let alone a measurement of mycotoxin levels in human blood before and after an ozone-based treatment.

Evidence-based steps for mold exposure

For someone concerned about a moldy building, established steps do not involve blood treatment of any kind. CDC recommends removing visible mold and, critically, fixing the underlying moisture problem, since mold returns if the water source is not addressed [1]. Anyone with respiratory symptoms, new or worsening asthma, or allergy symptoms after moving into a water-damaged space has grounds for a conventional allergy or pulmonology evaluation, including standard mold-specific testing where clinically appropriate, rather than the specialty biomarker panels CIRS practitioners often order. People who are immune-compromised or have chronic lung disease and suspect a mold-related infection should be evaluated promptly by their physician given the higher stakes of a missed diagnosis in that group. Someone who has already pursued a CIRS diagnosis and wants to try the one protocol a sympathetic review found clinical evidence for should understand that it is a specific, named, multi-step program of visual contrast sensitivity testing, binders, and other steps, not a general label covering any blood or detox treatment a clinic offers under a CIRS banner. Before paying for EBO2 or any similar procedure, comparing claims across this site’s clinic directory is a reasonable check on how consistent, or inconsistent, the marketing language really is.

Bottom line

Mold causes real, documented health effects, mainly respiratory and allergic, and mold infections are a genuine risk for immune-compromised people [1]. CIRS is a far more contested diagnosis, and even a review sympathetic to it found clinical evidence for only one treatment protocol, which does not include ozone therapy [2]. The single EBOO case report that touches on toxin markers involved one patient, no control group, and no demonstrated symptom benefit [4], while ozone’s real, well-documented role in reducing mycotoxins is industrial, applied to grain and nuts, not to human blood [3]. Anyone concerned about mold exposure is better served by fixing the building and getting a conventional medical evaluation than by a blood treatment marketed on the strength of an unrelated food-safety literature. A clinic that leads with EBO2 before recommending an inspection of the building itself, or before ordering standard allergy and respiratory testing, is proposing to treat a downstream symptom while leaving the source of exposure in place, an approach that does not match how CDC frames the problem or how the established medical literature on mold exposure is organized.